Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial
NCT04839354
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
271
Enrollment
OTHER
Sponsor class
Conditions
Sickle Cell Disease
Interventions
DRUG:
L-Arginine Hydrochloride
OTHER:
Normal saline
Sponsor
Claudia R. Morris
Collaborators
[object Object]